biblioteca virtual en salud

Búsqueda | Gripe por A(H1N1)

  • BIREME | OPAS | OMS logo
 

Historico de búsqueda  ()

Su selección  ()

 0 documento(s) seleccionado(s).

Enviar por email

Ud. tiene 0 documento(s) seleccionado(s).

Ningún documento seleccionado

 
Resultados  1-12 de 218
1.

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

Autor(es): Okomo-Adhiambo M; Nguyen HT; Abd Elal A; Sleeman K; Fry AM; Gubareva LV
Fuente: Influenza Other Respir Viruses;8(2): 258-65, 2014 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24299049
Resumen: BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC50 values indicative of clinically relevant resistance and insufficient harmonization of NI testing methodologies among surveillance laboratories. In 2012, the WHO working group on influenza antiviral susceptibility (mas)
2.

Antiviral Susceptibility of Variant Influenza A(H3N2)v Viruses Isolated in the United States from 2011 to 2013.

Autor(es): Sleeman K; Mishin VP; Guo Z; Garten RJ; Balish A; Fry AM; Villanueva J; Stevens J; Gubareva LV
Fuente: Antimicrob Agents Chemother;58(4): 2045-51, 2014 Apr.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24449767
Resumen: Since 2011, outbreaks caused by influenza A(H3N2) variant [A(H3N2)v] viruses have become a public health concern in the United States. The A(H3N2)v viruses share the A(H1N1)pdm09 M gene containing the marker of M2 blocker resistance, S31N, but do not contain any known molecular markers associated with resistance to neuraminidase (NA) inhibitors (NAIs). Using a fluorescent NA inhibition (NI) assay, the susceptibilities of recovered A(H3N2)v viruses (n = 168) to FDA-approved (oseltamivir and (mas)
3.

1,2,3-Triazole-containing derivatives of rupestonic acid: Click-chemical synthesis and antiviral activities against influenza viruses.

Autor(es): He YW; Dong CZ; Zhao JY; Ma LL; Li YH; Aisa HA
Fuente: Eur J Med Chem;76: 245-55, 2014 Apr 9.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24583605
Resumen: Two series of rupestonic acid derivatives, (1-substituted-1H-1,2,3-triazol-4-yl)methyl 2-((5R,8S,8aS)-3,8-dimethyl-2-oxo-1,2,4,5,6,7,8,8a-octahydroazulen-5-yl)acrylate and N-(1-substituted-1H-1,2,3-triazol-4-yl)methyl 2-((5R,8S,8aS)-3,8-dimethyl-2-oxo-1,2,4,5,6,7,8,8a-octahydroazulen-5-yl)acrylamide were easily and efficiently synthesized via click chemistry. These compounds were tested for their in vitro activities against various strains of influenza A virus (H1N1, oseltamivir resistant (mas)
4.

Outpatient influenza antiviral prescription trends with influenza-like illness in the USA, 2008-2010.

Autor(es): Suda KJ; Regen SM; Lee TA; Easterling JL; Hunkler RJ; Danziger LH
Fuente: Int J Antimicrob Agents;43(3): 279-83, 2014 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24373618
Resumen: The 2009 novel H1N1 influenza A virus (H1N1) became a global pandemic. Data on antiviral prescriptions by location from 2008 to 2010 have not been reported. The purpose of this study was to assess antiviral geographic trends and correlation with influenza-like illness (ILI) over 3 years. Percent of outpatient ILI visits and antiviral prescriptions from 1 January 2008 to 31 December 2010 were included. Linear regression was used to assess correlation. In total, 14 million antivirals were dis (mas)
5.

Antiviral effect of flavonol glycosides isolated from the leaf of Zanthoxylum piperitum on influenza virus.

Autor(es): Ha SY; Youn H; Song CS; Kang SC; Bae JJ; Kim HT; Lee KM; Eom TH; Kim IS; Kwak JH
Fuente: J Microbiol;52(4): 340-4, 2014 Apr.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24682996
Resumen: The ethanol extract of Zanthoxylum piperitum (L.) DC. showed in vitro antiviral activity against influenza A virus. Three flavonol glycosides were isolated from the EtOAc fraction of Z. piperitum leaf by means of activity-guided chromatographic separation. Structures of isolated compounds were identified as quercetin 3-O-ß-D-galactopyranoside (1), quercetin 3-O-α-L-rhamnopyranoside (2), kaempferol 3-O-α-L-rhamnopyranoside (3) by comparing their spectral data with literature values. T (mas)
6.

Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic.

Autor(es): Taylor G; Mitchell R; Fernandes R; McGeer A; Frenette C; Suh KN; Wong A; Katz K; Wilkinson K; Amihod B; Gravel D
Fuente: Antimicrob Resist Infect Control;3(1): 2, 2014.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24405855
Resumen: BACKGROUND: Multiple observational studies have associated antiviral treatment of patients hospitalized with influenza with improved outcome, including reduced mortality. During the 2009-2010 H1N1 pandemic increased use of antiviral treatment of hospital patients was reported. We have carried out prospective surveillance for influenza in patients in a large network of Canadian hospitals since 2006. We wished to assess trends in antiviral use in the two seasons (2010-2011 and 2011-2012) sinc (mas)
8.

Impact of medical and behavioural factors on influenza-like illness, healthcare-seeking, and antiviral treatment during the 2009 H1N1 pandemic: USA, 2009-2010.

Autor(es): Biggerstaff M; Jhung MA; Reed C; Garg S; Balluz L; Fry AM; Finelli L
Fuente: Epidemiol Infect;142(1): 114-25, 2014 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23522400
Resumen: We analysed a cross-sectional telephone survey of U.S. adults to assess the impact of selected characteristics on healthcare-seeking behaviours and treatment practices of people with influenza-like illness (ILI) from September 2009 to March 2010. Of 216,431 respondents, 8.1% reported ILI. After adjusting for selected characteristics, respondents aged 18-64 years with the following factors were more likely to report ILI: a diagnosis of asthma [adjusted odds ratio (aOR) 1.88, 95% CI 1.67-2.13 (mas)
9.

Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.

Autor(es): Pan P; Li L; Li Y; Li D; Hou T
Fuente: Antiviral Res;100(2): 356-64, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24055835
Resumen: Neuraminidase inhibitors (NAIs) play vital roles in controlling human influenza epidemics and pandemics. However, the emergence of new human influenza virus mutant strains resistant to existing antiviral drugs has been becoming a major challenge. Therefore, it is critical to uncover the mechanisms of drug resistance and seek alternative treatments to combat drug resistance. In this study, molecular dynamics (MD) simulations and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) wer (mas)
10.

Estimated impact of aggressive empirical antiviral treatment in containing an outbreak of pandemic influenza H1N1 in an isolated First Nations community.

Autor(es): Xiao Y; Patel Z; Fiddler A; Yuan L; Delvin ME; Fisman DN
Fuente: Influenza Other Respir Viruses;7(6): 1409-15, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23879801
Resumen: BACKGROUND: The 2009 influenza A (H1N1) pandemic was mild by historical standards, but was more severe in isolated Canadian Indigenous communities. Oseltamivir was used aggressively for outbreak control in an isolated northern Ontario First Nations community. We used mathematical modeling to quantify the impact of antiviral therapy on the course of this outbreak. METHODS: We used both a Richards growth model and a compartmental model to evaluate the characteristics of the outbreak based on (mas)
11.

Differential use of antivirals for treatment of patients with influenza A(H1N1)pdm09 in Germany.

Autor(es): Reuss A; Dehnert M; Buda S; Haas W
Fuente: Influenza Other Respir Viruses;7(6): 1427-32, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 23957666
Resumen: BACKGROUND: The World Health Organization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness. OBJECTIVES: The aim of this study was to determine the proportion of cases with laboratory-confirmed A(H1N1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (H1N1) 2009 and to investigate factors associated with the use of antivirals. METHODS: We analyzed cases with laboratory-confirmed A (mas)
12.

Detection and management of antiviral resistance for influenza viruses.

Autor(es): Boivin G
Fuente: Influenza Other Respir Viruses;7 Suppl 3: 18-23, 2013 Nov.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 24215378
Resumen: Neuraminidase inhibitors (NAIs) are first-line agents for the treatment and prevention of influenza virus infections. As for other antivirals, the development of resistance to NAIs has become an important concern particularly in the case of A(H1N1) viruses and oseltamivir. The most frequently reported change conferring oseltamivir resistance in that viral context is the H275Y neuraminidase mutation (N1 numbering). Recent studies have shown that, in the presence of the appropriate permissive (mas)
Resultados  1-12 de 218